Agios Pharmaceuticals (AGIO) In Focus On Earnings As Undervalued Narrative Holds

Simply Wall St.04:19

AdvertisementEarnings event puts Agios Pharmaceuticals stock in focus Agios Pharmaceuticals (AGIO) reported second quarter 2026 results on July 30, with revenue of US$44.75 million and a net loss of ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2658675029?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-08-09 04:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2658675029","market":"sg","top_or_hot":-1,"title":"Agios Pharmaceuticals (AGIO) In Focus On Earnings As Undervalued Narrative Holds","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementEarnings event puts Agios Pharmaceuticals stock in focus Agios Pharmaceuticals (AGIO) reported second quarter 2026 results on July 30, with revenue of US$44.75 million and a net loss of ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-agio/agios-pharmaceuticals/news/agios-pharmaceuticals-agio-in-focus-on-earnings-as-undervalu\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Agios Pharmaceuticals (AGIO) In Focus On Earnings As Undervalued Narrative Holds</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAgios Pharmaceuticals (AGIO) In Focus On Earnings As Undervalued Narrative Holds\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-09 04:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-agio/agios-pharmaceuticals/news/agios-pharmaceuticals-agio-in-focus-on-earnings-as-undervalu><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementEarnings event puts Agios Pharmaceuticals stock in focus Agios Pharmaceuticals (AGIO) reported second quarter 2026 results on July 30, with revenue of US$44.75 million and a net loss of ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-agio/agios-pharmaceuticals/news/agios-pharmaceuticals-agio-in-focus-on-earnings-as-undervalu\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AGIO","symbol_name":"Agios Pharmaceuticals, Inc.","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-agio/agios-pharmaceuticals/news/agios-pharmaceuticals-agio-in-focus-on-earnings-as-undervalu","article_id":"2658675029","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-agio/agios-pharmaceuticals/news/agios-pharmaceuticals-agio-in-focus-on-earnings-as-undervalu","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2658675029","pubTimestamp":1786220398,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Earnings event puts Agios Pharmaceuticals stock in focus\nAgios Pharmaceuticals (AGIO) reported second quarter 2026 results on July 30, with revenue of US$44.75 million and a net loss of US$100.7 million. Revenue and loss figures also shifted for the first half.\nSee our latest analysis for Agios Pharmaceuticals.\nThe earnings release appears to have sharpened investor attention on Agios Pharmaceuticals, with a 7.5% 7 day share price return and a 16.1% 90 day share price return standing against...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"AGIO":"Agios Pharmaceuticals, Inc."},"translate_title":"Agios Pharmaceuticals (AGIO) 关注盈利，因为被低估的说法依然存在","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AGIO":1.5},"content_text":"AdvertisementEarnings event puts Agios Pharmaceuticals stock in focus Agios Pharmaceuticals (AGIO) reported second quarter 2026 results on July 30, with revenue of US$44.75 million and a net loss of US$100.7 million. Revenue and loss figures also shifted for the first half. See our latest analysis for Agios Pharmaceuticals. The earnings release appears to have sharpened investor attention on Agios Pharmaceuticals, with a 7.5% 7 day share price return and a 16.1% 90 day share price return standing against a 1 year total shareholder return that is down 9.8%. Overall, short term momentum has picked up even though longer term returns remain mixed. If you are looking beyond Agios Pharmaceuticals for other potential ideas in healthcare and biotech, this could be a helpful moment to scan 43 healthcare AI stocks. The recent jump in Agios Pharmaceuticals shares follows stronger quarterly revenue and a smaller loss, which some investors may see as a business shift and others as sentiment chasing earnings headlines. The valuation section below tests which view holds up. Most Popular Narrative: 26.7% Undervalued At a last close of $32.27 versus a fair value estimate of $44.00, the most followed narrative frames Agios Pharmaceuticals as materially undervalued and heavily dependent on one key asset.  Agios's revenue growth is highly reliant on the success and expansion of PYRUKYND into new indications (thalassemia, sickle cell disease), exposing the company to significant revenue volatility if these launches or subsequent clinical/pipeline assets face setbacks, delays, or do not achieve expected uptake, negatively impacting both top-line growth and long-term earnings stability.  Read the complete narrative. Read the complete narrative. Want to understand why this fair value leans so heavily on PYRUKYND and Aqvesme? The narrative weighs aggressive revenue expansion and potential future margin improvement against ongoing losses and a rich implied earnings multiple. The balance between rapid top line forecasts and delayed profitability is doing most of the work in that $44.00 figure. Result: Fair Value of $44.00 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, Agios Pharmaceuticals still faces concentration risk around PYRUKYND and Aqvesme, and any regulatory setbacks or safety concerns could quickly weaken the current undervaluation story. Find out about the key risks to this Agios Pharmaceuticals narrative. Another View: Agios Pharmaceuticals looks expensive on sales While one narrative pegs Agios Pharmaceuticals as 26.7% undervalued on a fair value estimate of $44.00, the picture changes when you look at simple sales multiples. The stock trades on a P/S of 19.6x, compared with 11.6x for the US Biotechs industry, 6.5x for peers, and a fair ratio of just 0.2x. That gap points to meaningful valuation risk if sentiment cools. For a closer look at how this pricing stacks up against fundamentals, including why the current P/S sits so far above the fair ratio, See what the numbers say about this price — find out in our valuation breakdown. NasdaqGS:AGIO P/S Ratio as at Aug 2026Next Steps The mix of risks and rewards around Agios Pharmaceuticals can feel finely balanced, so it helps to move quickly and test the data yourself. To see how those concerns and opportunities stack up side by side, start with the 2 key rewards and 1 important warning sign. Looking for more investment ideas beyond Agios Pharmaceuticals? If Agios Pharmaceuticals has your attention, do not stop here. The next strong idea could be one screen away, so give yourself more options now.  Target potential mispricings by checking companies that appear out of favor yet financially sound through the 51 high quality undervalued stocks. Strengthen your focus on resilience and capital protection by reviewing companies highlighted in the 79 resilient stocks with low risk scores. Spot lesser known opportunities with healthy fundamentals before the crowd by scanning the screener containing 19 high quality undiscovered gems.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2658675029","isCrawlerRequest":true}